Manufacturing Plants Under Scrutiny By Justice Department

Source: PharmaManufacturing.com

Jun 10, 2013

Forbes

After numerous violations and recalls in both the US and abroad, the United States Department of Justice (DOJ) has promised to take an "especially hard look" at plants to ensure the safety and purity of prescription drugs. Though the FDA continues to have a key role in pharma investigations and regulations, the DOJ will be taking a more active role following the False Claims Act. Read the full story.
Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments